List of Excipients in Branded Drug ELTROMBOPAG

« Back to Dashboard

Generic Drugs Containing ELTROMBOPAG

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	eltrombopag olamine	0054-0962	CROSPOVIDONE
Hikma Pharmaceuticals USA Inc	eltrombopag olamine	0054-0962	FERRIC OXIDE RED
Hikma Pharmaceuticals USA Inc	eltrombopag olamine	0054-0962	FERROSOFERRIC OXIDE

What are the Most Frequently-Used Excipients in ELTROMBOPAG?

# Of NDCs	Excipient
4	CELLULOSE, MICROCRYSTALLINE
1	CROSPOVIDONE
1	FD&C BLUE NO. 2

Eltrombopag Excipient Strategy and Commercial Opportunities

Last updated: October 21, 2026

Eltrombopag is an oral thrombopoietin-receptor agonist marketed primarily as eltrombopag olamine under Promacta in the United States and Revolade in many other markets. The strongest excipient opportunities are in cation-controlled formulations, pediatric powder for oral suspension, taste masking, low-dose dose flexibility, and formulations that reduce food and mineral-interaction constraints.

The central formulation issue is eltrombopag’s ability to chelate polyvalent cations. Calcium, iron, magnesium, and aluminum can reduce exposure, requiring administration separation from dairy products, antacids, mineral supplements, and calcium-containing foods. An excipient strategy that avoids reactive minerals and improves dispersion, palatability, dose uniformity, and storage stability can create commercial value in generic, pediatric, hospital, and emerging-market products.

What is eltrombopag and how is it formulated?

Eltrombopag is a small-molecule, orally administered thrombopoietin-receptor agonist. It is supplied as eltrombopag olamine rather than as the neutral parent compound.

The principal approved dosage forms are:

Dosage form	Typical strengths	Commercial role
Film-coated tablet	12.5, 25, 50 and 75 mg	Adult and older pediatric treatment
Powder for oral suspension	12.5 and 25 mg per packet	Pediatric dosing and patients unable to swallow tablets

Promacta is approved for several hematologic indications, including chronic immune thrombocytopenia, severe aplastic anemia, and thrombocytopenia associated with chronic hepatitis C in specific treatment settings. The approved indication mix varies by jurisdiction. The FDA label identifies administration limitations involving food and polyvalent cations.[1]

What inactive ingredients are used in eltrombopag tablets?

The U.S. Promacta tablet formulation uses conventional direct-compression excipients, including:

• Mannitol
• Microcrystalline cellulose
• Povidone
• Sodium starch glycolate
• Magnesium stearate
• Film-coating excipients, including hypromellose and titanium dioxide
• Colorants that vary by tablet strength

The excipient profile is relatively conventional. The commercial differentiation does not come from a complex delivery system. It comes from maintaining eltrombopag exposure while managing the active ingredient’s interaction with polyvalent cations, food, and gastrointestinal conditions.

What excipients are used in eltrombopag powder for oral suspension?

The powder formulation uses a water-dispersible excipient system designed for reconstitution. The label identifies mannitol, sucralose, and xanthan gum among the inactive ingredients.[1]

That combination supports several functional requirements:

• Mannitol provides bulk and contributes to powder handling.
• Xanthan gum increases suspension viscosity and helps maintain dose uniformity.
• Sucralose provides sweetness and improves pediatric acceptability.
• The formulation must disperse rapidly in water without forming persistent agglomerates.

The powder dosage form has a higher excipient-development burden than the tablet because the product must deliver consistent dose content after reconstitution, remain acceptable to children, and meet microbial and in-use stability requirements.

Why are polyvalent cations the main excipient risk?

Eltrombopag binds polyvalent cations in the gastrointestinal tract. The FDA labeling instructs patients to administer eltrombopag at least two hours before or four hours after products containing polyvalent cations, including antacids, dairy products, mineral supplements, and certain fortified foods.[1]

This creates a direct excipient-screening requirement. Formulators should generally exclude or tightly control:

• Calcium salts, including calcium carbonate and calcium phosphate
• Magnesium salts
• Aluminum-containing compounds
• Iron salts
• Zinc and other mineral supplements
• Mineral-containing flavors or nutritional components
• Calcium-based buffering systems

The issue is not limited to intentionally added minerals. Trace elemental impurities, processing aids, pigments, and container-closure components can also become relevant during development and stability testing.

How should an excipient-screening program be designed?

A practical screening program should evaluate:

1. Elemental calcium, magnesium, iron, aluminum and zinc content.
2. Chelation or adsorption across the product’s intended pH range.
3. Dissolution and dispersion in biorelevant media.
4. Exposure after administration with low-calcium and standard meals.
5. Compatibility with packaging and reconstitution water.
6. Stability under temperature and humidity stress.
7. Dose uniformity for low-strength tablets and pediatric suspensions.

Excipient selection should prioritize compendial, globally available materials with low elemental variability. Supplier controls should include certificates for elemental impurities rather than relying only on standard identity and purity testing.

What formulation patents and intellectual-property opportunities protect eltrombopag?

Eltrombopag’s intellectual-property position has historically included composition-of-matter, pharmaceutical composition, formulation, salt, dosage-form, and method-of-use rights. The original regulatory exclusivity period has expired, but formulation and use claims can continue to affect generic entry and product differentiation.

The relevant patent categories are:

Patent category	Typical protected subject matter	Commercial relevance
Composition of matter	Eltrombopag chemical structure or related salts	Usually the earliest and broadest protection
Salt and solid-state forms	Eltrombopag olamine, polymorphs, hydrates and crystallinity	Can affect manufacturing and bioavailability
Pharmaceutical compositions	Excipient combinations, dosage units and release characteristics	Relevant to tablet and suspension competitors
Method of use	Treatment of ITP, aplastic anemia and other thrombocytopenic disorders	Can affect label carve-outs and litigation
Pediatric formulations	Powder, reconstitution, taste-masked or age-specific products	Supports pediatric generic differentiation
Manufacturing processes	Crystallization, purification, granulation and impurity control	Can create non-infringing process routes

The FDA Orange Book remains the operative U.S. source for listed patents and regulatory exclusivity. Patent expiry must be assessed by patent number, claims, terminal disclaimers, pediatric extensions, and any litigation settlement rather than by relying on a single “Promacta expiry date.”[2]

When did eltrombopag lose regulatory exclusivity?

Eltrombopag’s original new chemical entity exclusivity and orphan-drug exclusivity periods have expired. The commercial barrier now depends primarily on patent claims, regulatory requirements, manufacturing capability, and market access.

The main regulatory milestones were:

Event	Date
FDA approval of Promacta for chronic ITP	November 2008
U.S. approval of additional indications	Subsequent supplements
Introduction of pediatric powder for oral suspension	FDA-approved supplemental product
Original NCE exclusivity	Expired
Original orphan exclusivity periods	Expired
Current competitive barrier	Listed patents, litigation, formulation complexity and market access

FDA approval does not eliminate formulation risk. A generic applicant must demonstrate pharmaceutical equivalence and bioequivalence, while a 505(b)(2) applicant may pursue a differentiated dosage form or administration profile with a different regulatory strategy.[3]

What commercial opportunities exist for eltrombopag excipient innovation?

1. Pediatric powder and taste-masked products

Pediatric thrombocytopenia and aplastic anemia remain the clearest dosage-form opportunity. A successful product must address:

• Bitter or metallic active-ingredient taste
• Rapid wetting and dispersion
• Low sedimentation during dosing
• Accurate withdrawal from an oral syringe
• Dose flexibility below the standard tablet strengths
• Low microbial risk after reconstitution
• Acceptable storage and in-use stability

Potential excipient platforms include optimized xanthan gum systems, alternative suspending agents, polymeric taste-masking coatings, ion-exchange resins, lipid-based taste barriers, and multiparticulate systems.

A new product may command value if it reduces preparation errors or improves adherence, even without materially improving systemic exposure.

2. Mineral-free formulations for patients receiving supplements

Many patients with chronic liver disease, anemia, malnutrition, or hematologic disorders receive iron, calcium, magnesium, or multivitamin products. An eltrombopag product that cannot eliminate the underlying chelation interaction can still reduce administration complexity through:

• Clearer dosing instructions
• A co-packaged administration schedule
• A low-volume pediatric suspension
• A formulation with rapid and predictable dispersion
• Packaging that separates the drug from mineral-containing products

A true reduction in cation sensitivity would require clinical pharmacokinetic evidence. It cannot be inferred from dissolution data alone.

3. Low-strength and dose-flexible products

Eltrombopag treatment is titrated according to platelet response and indication. Dose adjustments create demand for 12.5 mg units, combination dosing, and pediatric dose flexibility.

Commercial opportunities include:

• Scored or mini-tablets
• Multiparticulates filled into capsules or sachets
• Unit-dose powders
• Oral granules
• Dispersible tablets
• Oral syringes calibrated for low-volume administration

The principal technical challenge is content uniformity. Low-dose products must prevent segregation during blending, filling, shipping, and reconstitution.

4. Improved powder reconstitution

A next-generation powder could compete through reconstitution performance rather than a new active ingredient. Development targets include:

• Faster wetting
• Reduced foaming
• Lower sedimentation
• More complete redispersion after standing
• Longer in-use stability
• Lower dosing-device residual volume
• Improved portability

Excipients such as optimized suspending polymers, wetting agents, porous carriers, and engineered granules may improve handling. Any surfactant or polymer must be evaluated for impact on eltrombopag solubilization and cation binding.

5. Manufacturing-cost reduction

The approved tablet uses standard excipients, creating a potential cost advantage for manufacturers that improve powder flow, granulation yield, compression speed, and coating efficiency.

Relevant process opportunities include:

• Direct compression with improved powder flow
• Dry granulation to reduce solvent use
• Continuous manufacturing
• Lower-cost film-coating systems
• Regional excipient sourcing
• Reduced tablet weight
• More robust control of eltrombopag particle size

A lower-cost formulation has commercial value in markets where Promacta or Revolade pricing is limited by reimbursement controls.

How does eltrombopag compare with competing thrombopoietin-receptor agonists?

Eltrombopag competes with avatrombopag, lusutrombopag, and injectable romiplostim. The products differ materially in administration, food interaction, formulation complexity, and delivery route.

Product	Active ingredient	Route	Principal excipient or administration issue
Promacta/Revolade	Eltrombopag olamine	Oral	Polyvalent-cation chelation and food restrictions
Doptelet	Avatrombopag	Oral	Food administration is part of labeled dosing
Mulpleta	Lusutrombopag	Oral	Short-course use in selected chronic liver disease patients
Nplate	Romiplostim	Subcutaneous injection	Reconstitution and biologic handling rather than oral excipient interaction

Eltrombopag has a broader long-term oral treatment profile in several hematologic settings, but its mineral interaction creates a practical disadvantage. Avatrombopag may have an administration advantage in settings where dosing with food is easier than separating treatment from calcium, iron, magnesium, or aluminum products.[4]

What FDA regulatory pathway applies to new eltrombopag products?

Generic tablets

A conventional generic tablet may use an abbreviated new drug application if it matches the reference listed drug in dosage form, strength, route, conditions of use, and labeling, subject to permissible labeling differences. The applicant must establish pharmaceutical equivalence and bioequivalence.[3]

Excipient changes are possible, but they must not alter safety, efficacy, quality, dissolution, or bioequivalence.

Pediatric suspension or alternative oral dosage form

A new powder, suspension, granule, or dispersible dosage form may require a 505(b)(2) application if it differs materially from the reference product. This route can support:

• A new dosage form
• A different administration method
• A pediatric formulation
• Modified dosing instructions
• New pharmacokinetic or usability claims

The regulatory value increases when the product solves a clinically documented administration problem rather than simply changing flavor or color.

International markets

Eltrombopag products face different regulatory and market-access requirements across the United States, European Union, Japan, China, and emerging markets. Geographic opportunity is strongest where:

• The originator price remains high.
• Pediatric access is limited.
• Oral suspension products are unavailable.
• Mineral supplements are commonly used.
• Local generic manufacturers have strong hospital or tender access.
• Regulatory pathways recognize established active substances but permit differentiated dosage forms.

European and other non-U.S. markets may use different naming, strength, excipient, and product-information conventions. Global development should therefore avoid an excipient system that depends on a single-region supplier or non-standard material.

Which companies are challenging eltrombopag exclusivity?

Generic and specialty pharmaceutical companies have commercial incentives to enter the eltrombopag market because the originator product has generated substantial global sales. Novartis reported Promacta/Revolade sales of approximately $1.17 billion in 2023.[5]

Potential competitors include companies with:

• Existing hematology portfolios
• Generic oral solid-dose manufacturing
• Pediatric liquid development capability
• 505(b)(2) experience
• U.S. ANDA infrastructure
• Strong tender access in Europe and emerging markets

The most commercially meaningful challenge is not necessarily the first standard tablet. It may be a differentiated competitor that combines a generic active ingredient with a pediatric suspension, lower-cost supply chain, or superior distribution.

Paragraph IV activity, ANDA approvals, and litigation must be assessed against current FDA Orange Book and court records. A patent challenge can produce a launch opportunity, but a settlement may delay entry or impose licensed-entry conditions. No commercial forecast should treat an ANDA filing as equivalent to market launch.

What litigation and settlement issues affect generic launch?

Eltrombopag litigation can involve:

• Orange Book-listed formulation patents
• Salt or solid-state claims
• Method-of-use patents
• Paragraph IV certification
• Inducement allegations based on labeling
• Contractual settlement restrictions
• Pediatric or low-dose formulations
• Manufacturing-process patents

A generic applicant may pursue a “skinny label” that omits patented indications, but the commercial usefulness of that strategy depends on whether the remaining indications support sufficient volume and whether the proposed labeling creates induced-infringement risk.

The highest-risk launch scenario is a first-filer or early entrant facing a listed patent with claims broad enough to cover the commercial tablet or powder formulation. The lower-risk opportunity is a non-infringing pediatric formulation supported by a distinct excipient and process architecture.

How strong is the eltrombopag patent estate?

The estate is weaker than during the originator’s launch period because basic regulatory exclusivities have expired and the active ingredient is established. It remains commercially relevant where later-expiring claims cover:

• Specific eltrombopag olamine solid forms
• Particle-size or crystallinity requirements
• Pharmaceutical compositions
• Pediatric powders and suspensions
• Dosing regimens
• Manufacturing processes

Patent strength depends on claim scope, validity, written-description support, prosecution history, and the ability to design around the claim. Formulation patents are most valuable when they combine a narrow excipient system with clinically meaningful performance. Broad claims to routine excipients such as mannitol, cellulose, or magnesium stearate are generally less defensible than claims tied to defined ratios, particle properties, reconstitution performance, or demonstrated pharmacokinetic effects.

What is the highest-value excipient strategy?

The strongest strategy is a mineral-controlled, pediatric-capable platform with three product configurations:

1. A low-cost, bioequivalent film-coated tablet using globally available excipients.
2. A palatable powder for oral suspension with strong redispersion and dose uniformity.
3. A differentiated low-dose product for titration and pediatric use.

The formulation should avoid intentionally added polyvalent cations, control elemental impurities, use a robust taste-masking approach, and generate comparative data on dispersion, dissolution, food effect, and cation compatibility.

Key Takeaways

• Eltrombopag’s central formulation problem is chelation with calcium, iron, magnesium, aluminum, and related polyvalent cations.
• Approved products include film-coated tablets and powder for oral suspension.
• Pediatric powder, taste masking, dose flexibility, and improved reconstitution are the strongest excipient-led opportunities.
• A standard generic tablet is likely to compete primarily on cost and supply reliability.
• A differentiated suspension or low-dose platform can support higher commercial value.
• Original NCE and orphan exclusivities have expired; current entry risk depends on patents, litigation, regulatory pathway, and manufacturing capability.
• Promacta/Revolade generated approximately $1.17 billion in 2023 sales, indicating substantial generic and specialty-product exposure.
• The most defensible new intellectual property will likely concern defined formulation performance, solid-state control, reconstitution behavior, or manufacturing processes rather than routine excipient substitution.

FAQs

Can calcium carbonate be used in an eltrombopag formulation?

It is technically possible to include calcium carbonate only if the formulation is shown not to reduce eltrombopag availability. Because calcium can bind eltrombopag, calcium carbonate is generally an unfavorable excipient choice without strong compatibility and pharmacokinetic data.

Is eltrombopag suitable for an orally disintegrating tablet?

An orally disintegrating tablet could improve administration for patients with swallowing difficulty, but it would require control of taste, rapid disintegration, dose uniformity, and cation-free excipient selection. The dosage form would not automatically eliminate food or mineral-interaction restrictions.

Which excipients are most suitable for an eltrombopag pediatric suspension?

Mannitol, sucralose, and xanthan gum are established excipient choices in the approved powder formulation. Alternative polymers, sweeteners, and taste-masking systems may be developed if they maintain dose uniformity, stability, palatability, and bioequivalence.

Can a generic eltrombopag product use a different salt?

A different salt or free-form active ingredient may not qualify as a straightforward generic equivalent. It could require additional pharmaceutical, bioequivalence, stability, and regulatory justification, potentially through a 505(b)(2) pathway in the United States.

Does an excipient change avoid eltrombopag patent infringement?

An excipient change may avoid a formulation claim if the redesigned product falls outside the claim scope. It does not avoid composition-of-matter, salt, solid-state, method-of-use, or manufacturing-process claims. A claim-by-claim analysis is required.

References

1. U.S. Food and Drug Administration. (2023). Promacta (eltrombopag olamine) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Generic drug guidance. FDA.

4. U.S. Food and Drug Administration. (2023). Doptelet (avatrombopag), Mulpleta (lusutrombopag), and Nplate (romiplostim) prescribing information. FDA.

5. Novartis AG. (2024). Annual report 2023. Novartis.